HK1122738A1 - Trpa1 inhibitors for treating pain - Google Patents

Trpa1 inhibitors for treating pain

Info

Publication number
HK1122738A1
HK1122738A1 HK09100626.3A HK09100626A HK1122738A1 HK 1122738 A1 HK1122738 A1 HK 1122738A1 HK 09100626 A HK09100626 A HK 09100626A HK 1122738 A1 HK1122738 A1 HK 1122738A1
Authority
HK
Hong Kong
Prior art keywords
treating pain
trpa1 inhibitors
trpa1
inhibitors
pain
Prior art date
Application number
HK09100626.3A
Other languages
English (en)
Inventor
Magdalene M Moran
Christopher Fanger
Jayhong A Chong
Colleen Mcnamara
Xiaoguang Zhen
Josh Mandel-Brehm
Original Assignee
Hydra Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hydra Biosciences Inc filed Critical Hydra Biosciences Inc
Publication of HK1122738A1 publication Critical patent/HK1122738A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
HK09100626.3A 2005-12-22 2009-01-21 Trpa1 inhibitors for treating pain HK1122738A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75366505P 2005-12-22 2005-12-22
US81789206P 2006-06-29 2006-06-29
PCT/US2006/049244 WO2007073505A2 (en) 2005-12-22 2006-12-22 Trpa1 inhibitors for treating pain

Publications (1)

Publication Number Publication Date
HK1122738A1 true HK1122738A1 (en) 2009-05-29

Family

ID=38189134

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09100626.3A HK1122738A1 (en) 2005-12-22 2009-01-21 Trpa1 inhibitors for treating pain

Country Status (10)

Country Link
US (6) US7671061B2 (zh)
EP (1) EP1962855B1 (zh)
JP (5) JP5858557B2 (zh)
CN (2) CN101384261B (zh)
AU (3) AU2006327181A1 (zh)
CA (1) CA2634152A1 (zh)
ES (1) ES2436225T3 (zh)
HK (1) HK1122738A1 (zh)
TW (4) TWI649092B (zh)
WO (1) WO2007073505A2 (zh)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1871420A4 (en) * 2005-04-15 2010-09-22 Univ North Carolina PROCESS FOR ENABLING CELL SURVIVAL VIA NEUROTROPHINE MIMETICS
RU2008144571A (ru) * 2006-04-12 2010-05-20 Мерк энд Ко., Инк. (US) Пиридиламидные антагонисты кальциевых каналов т-типа
WO2007150010A2 (en) * 2006-06-23 2007-12-27 Abbott Laboratories Cyclopropyl amine derivatives as histamin h3 receptor modulators
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
WO2008013861A2 (en) * 2006-07-27 2008-01-31 Redpoint Bio Corporation Screening assay for inhibitors of trpa1 activation by a lower alkyl phenol
JP4591599B2 (ja) * 2006-10-06 2010-12-01 アステラス製薬株式会社 消化管運動改善剤スクリーニング法
EP3663295A1 (en) 2007-06-22 2020-06-10 Eli Lilly And Co. 2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel
AU2015202546B8 (en) * 2007-06-22 2017-03-09 Eli Lilly And Company Methods and Compositions for Treating Disorders
JP5524071B2 (ja) 2007-10-24 2014-06-18 メルク・シャープ・アンド・ドーム・コーポレーション 複素環フェニルアミドｔ型カルシウムチャネルアンタゴニスト
EP2229364B1 (en) 2007-12-05 2015-02-25 Janssen Pharmaceutica, N.V. Dibenzoazepine and dibenzooxazepine trpa1 agonists
GEP20125574B (en) * 2008-01-11 2012-07-10 Glenmark Pharmaceuticals Sa Fused pyrimidine derivatives as trpv3 modulators
WO2009118596A2 (en) * 2008-03-26 2009-10-01 Glenmark Pharmaceuticals, S. A. Phthalimide derivatives as trpa1 modulators
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
WO2009137087A2 (en) * 2008-05-07 2009-11-12 Yale University A method for preventing or alleviating the noxious effects resulting from toxicant exposure
WO2009136889A1 (en) * 2008-05-08 2009-11-12 Nova Southeastern University Specific inhibitors for vascular endothelial growth factor receptors
US20110262395A1 (en) * 2008-05-08 2011-10-27 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
WO2009140517A1 (en) 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
WO2009140519A1 (en) * 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
US8318728B2 (en) 2008-05-14 2012-11-27 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
WO2009144548A1 (en) * 2008-05-28 2009-12-03 Glenmark Pharmaceuticals S.A. Imidazo [2,1-b] purine derivatives as trpa1 modulators
WO2009147079A1 (en) * 2008-06-02 2009-12-10 Janssen Pharmaceutica Nv 3,4-dihydropyrimidine trpa1 antagonists
WO2009152261A1 (en) * 2008-06-10 2009-12-17 Brandeis University Methods of insect control by inhibiting or modulating the trpa1 ion gated channel or family members
US7951814B2 (en) 2008-06-17 2011-05-31 Glenmark Pharmaceuticals, S.A. Quinazolinedione derivatives as TRPA1 modulators
WO2009158719A2 (en) * 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
WO2010036821A1 (en) * 2008-09-24 2010-04-01 Hydra Biosciences, Inc. Methods and compositions for treating respiratory disorders
KR101063352B1 (ko) * 2008-11-28 2011-09-07 고려대학교 산학협력단 Ｔｒｐａ１ 활성 억제 약물 및 이의 활용
TW201026700A (en) * 2008-12-22 2010-07-16 Hydra Biosciences Inc Compositions useful for treating disorders related to TRPA1
US8530487B1 (en) 2009-01-29 2013-09-10 Hydra Biosciences, Inc. Compounds useful for treating disorders related to TRPA1
AP2011005888A0 (en) * 2009-03-23 2011-10-31 Glenmark Pharmaceuticals Sa Isothiazolo-pyrimidinedione derivatives as TRPA1 modulators.
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
ES2551085T3 (es) * 2009-03-23 2015-11-16 Glenmark Pharmaceuticals S.A. Proceso para preparar derivados de pirimidina-diona condensados, útiles como moduladores de TRPA1
PT2411395E (pt) * 2009-03-23 2013-06-06 Glenmark Pharmaceuticals Sa Derivados de furopirimidinadiona como moduladores de trpa1
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2010132838A1 (en) * 2009-05-14 2010-11-18 Hydra Biosciences, Inc. Compounds useful for treating disorders related to trpa1
WO2010138879A1 (en) * 2009-05-29 2010-12-02 Hydra Biosciences, Inc. Compounds useful for treating disorders related to trpa1
WO2011012592A1 (en) * 2009-07-30 2011-02-03 F. Hoffmann-La Roche Ag Dihydropyrimidone amides as p2x7 modulators
AU2010303822A1 (en) 2009-10-07 2012-03-15 Merck Sharp & Dohme Corp. Novel TRPA1 antagonists
EP3470402B1 (en) 2009-11-12 2021-01-06 Pharmatrophix Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
DE102010002558A1 (de) * 2009-11-20 2011-06-01 Symrise Ag Verwendung physiologischer Kühlwirkstoffe und Mittel enthaltend solche Wirkstoffe
CN102822171B (zh) * 2010-03-26 2015-09-02 默克专利有限公司 作为自分泌运动因子抑制剂的苯并萘啶胺类
WO2011132017A1 (en) * 2010-04-19 2011-10-27 Glenmark Pharmaceuticals S.A. Pyrido[3,4-d]pyrimidinyl acetamide derivatives as trpa1 modulators
WO2012050641A2 (en) * 2010-06-08 2012-04-19 Hydra Biosciences, Inc Use of trpa1 antagonists to prevent or treat infections caused by biological-warfare agents
WO2011163312A2 (en) * 2010-06-22 2011-12-29 Children's Medical Center Corporation Improving efficacy of cancer therapy
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
WO2012050512A1 (en) 2010-10-12 2012-04-19 Astrazeneca Ab Trpa1 receptor antagonist
CA2814540A1 (en) * 2010-10-13 2012-04-19 Horacio Uri Saragovi Inhibitors of p75 receptor and their uses
EA023141B1 (ru) 2010-12-20 2016-04-29 Гленмарк Фармасьютикалс С.А. Соединения 2-амино-4-арилтиазола в качестве антагонистов trpa1
US20140024725A1 (en) * 2010-12-22 2014-01-23 Jéróme Aubert Modulators for trpa1 for the treatment of rosacea
CN103826637A (zh) 2011-06-13 2014-05-28 格兰马克药品股份有限公司 使用trpa1拮抗剂治疗呼吸疾患
JO3154B1 (ar) * 2011-06-17 2017-09-20 Glaxosmithkline Llc عوامل مضادة لـ trpv4
WO2012176105A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
EP2723329A1 (en) 2011-06-22 2014-04-30 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and a beta-2 agonist
WO2013014597A1 (en) 2011-07-25 2013-01-31 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a steroid
RU2014108885A (ru) * 2011-08-09 2015-09-20 Хайдра Байосайенсиз, Инк. Ингибирование транзиторного рецепторного потенциала ионного канала trpa1
US9309237B2 (en) 2011-09-06 2016-04-12 New York Blood Center, Inc. HIV inhibitors
WO2013084153A1 (en) 2011-12-05 2013-06-13 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
US9962430B2 (en) 2012-02-15 2018-05-08 Chirhoclin, Inc. Methods for treating pain associated with chronic pancreatitis
US11406718B2 (en) 2012-05-29 2022-08-09 Chirhoclin, Inc. Methods of detecting pancreobiliary ductal leaks
KR20150015488A (ko) * 2012-06-08 2015-02-10 그렌마크 파머수티칼스 에스. 아. 2-아미노-4-아릴티아졸 화합물의 아미드 및 그의 염
EP2869897A4 (en) 2012-07-06 2016-09-28 Univ Duke ACTIVATION OF THE TRPV4 ION CHANNEL BY PHYSICAL STIMULI AND IMPORTANT ROLE FOR TRPV4 IN ORGANIC INFLAMMATION AND JUCKREIZ
US20140163048A1 (en) * 2012-08-09 2014-06-12 Cubist Pharmaceuticals, Inc. Compositions with increased stability for inhibiting transient receptor potential ion channel trpa1
US9394308B2 (en) 2013-01-18 2016-07-19 Merck Sharp & Dohme Corp. Inhibiting the transient receptor potential A1 ion channel
CN105143229B (zh) * 2013-03-15 2017-06-30 海德拉生物科学有限公司 取代的黄嘌呤及其使用方法
GB201309333D0 (en) 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
CN103360393B (zh) * 2013-07-29 2016-01-06 上海万巷制药有限公司 茶碱乙酸的制备方法
MX2016004741A (es) 2013-10-15 2016-07-26 Glenmark Pharmaceuticals Sa Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
CA2936111C (en) 2014-01-06 2023-03-14 Algomedix, Inc. Trpa1 modulators
TWI676626B (zh) 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位ａ１離子通道
WO2016028325A1 (en) * 2014-08-22 2016-02-25 Duke University Trpa1 and trpv4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2016042501A1 (en) 2014-09-16 2016-03-24 Glenmark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
EP3193880B1 (en) 2014-09-19 2020-03-25 Eli Lilly and Company Inhibiting the transient receptor potential a1 ion channel
ES2764440T3 (es) 2014-09-19 2020-06-03 New York Blood Center Inc Fenilpirrolcarboxamidas sustituidas con actividad terapéutica en VIH
PT3231793T (pt) * 2014-12-12 2020-05-06 Japan Tobacco Inc Compostos de di-hidropirimidina-2-ona e utilizações médicas dos mesmos
US11229628B2 (en) 2015-01-09 2022-01-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
CN107624068B (zh) * 2015-06-05 2021-03-09 雀巢产品有限公司 包含肉桂醛和锌的组合物及此类组合物的使用方法
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
JP2019513749A (ja) 2016-04-07 2019-05-30 デューク ユニバーシティ 衛生化及び麻酔用のｔｒｐｖ４及びｔｒｐａ１の小分子二重阻害剤
US20210290524A1 (en) * 2016-09-06 2021-09-23 Children's Medical Center Corporation Topical trpv1 antagonists and methods and compositions thereof
EP3603610B1 (en) * 2017-03-30 2023-08-23 Mandom Corporation Trpa1 activity inhibitor
JP7231617B2 (ja) 2017-08-31 2023-03-01 ビーエーエスエフ ソシエタス・ヨーロピア 生理学的冷涼活性成分の使用、及びそのような活性成分を含む組成物
MX2020003341A (es) 2017-10-18 2020-09-17 Jubilant Epipad LLC Compuestos de imidazo-piridina como inhibidores de pad.
BR112020014584A2 (pt) 2018-01-31 2020-12-01 Eli Lilly And Company inibição do canal iônico do receptor de potencial transitório a1
CN108358925B (zh) * 2018-02-24 2021-04-06 中山大学 一种7,8-取代-3-甲基黄嘌呤类化合物及其制备方法和应用
AU2019228915A1 (en) 2018-02-28 2020-07-02 Japan Tobacco Inc. 4-methyldihydropyrimidinone compound and medicinal use thereof
US20210315811A1 (en) * 2018-09-05 2021-10-14 Sensory Cloud, Llc Formulations and compositions for ortho- and/or retro-nasal delivery and associated systems, methods and articles
CN109527341B (zh) * 2019-01-02 2022-04-22 中国科学院兰州化学物理研究所 一种多功能抗菌脱霉剂
US10758329B1 (en) 2019-08-20 2020-09-01 Raymond L. Wright, III Hydrating mouth guard
US11744878B2 (en) 2020-08-19 2023-09-05 Chirhoclin, Inc. Methods for treatment of COVID-19 syndrome
US11951082B2 (en) 2022-08-22 2024-04-09 Ford Therapeutics, Llc Composition of chlorhexidine
WO2024055006A2 (en) * 2022-09-09 2024-03-14 The Regents Of The University Of California Compositions for preventing transition from acute to chronic pain
CN116655635B (zh) * 2023-05-19 2024-01-26 济南爱思医药科技有限公司 黑茶茶碱衍生物及在制备药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04503205A (ja) * 1988-05-02 1992-06-11 ナフッチィ，エヌ，エリック 神経学的活性化合物
JP2627093B2 (ja) 1989-12-26 1997-07-02 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料
US5744316A (en) * 1992-12-22 1998-04-28 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
FR2809388B1 (fr) 2000-05-23 2002-12-20 Saint Gobain Vitrage Vitrage comprenant au moins une couche a proprietes thermochromes
US7018617B1 (en) * 2000-07-14 2006-03-28 California Institute Of Technology Methods and compositions associated with nociceptive pain
FR2815030A1 (fr) 2000-10-05 2002-04-12 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant et leur utilisation pour la preparation de medicaments
EA200400162A1 (ru) 2001-07-11 2005-06-30 Элан Фармасьютикалз, Инк. N-(3-амино-2-гидроксипропил)замещенные алкиламидные соединения
NZ533107A (en) * 2001-11-08 2007-04-27 Upjohn Co N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
BR0302965A (pt) * 2002-02-01 2005-02-09 King Pharmaceuticals Res & Dev Composto e método de tratar doenças mediadas por receptores de adenosina a2b
WO2003087158A2 (en) * 2002-04-16 2003-10-23 Bayer Healthcare Ag Regulation of human transient receptor potential channel
WO2004050833A2 (en) * 2002-11-27 2004-06-17 University Of North Carolina At Chapel Hill Glyceraldehyde 3-phosphate dehydrogenase-s(gapds), a glycolytic enzyme expressed only in male germ cells,is a target for male contraception
US7465581B2 (en) * 2002-12-18 2008-12-16 The Scripps Research Institute ANKTM1, a cold-activated TRP-like channel expressed in nociceptive neurons
EP1583821A4 (en) * 2003-01-15 2007-07-18 Millennium Pharm Inc METHODS AND COMPOSITIONS FOR TREATING UROLOGICAL DISORDERS USING GENES 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579
US20040197828A1 (en) * 2003-03-26 2004-10-07 Gaddy Dana P. Method for diagnosis and treatment of bone turnover
HRP20030324A2 (en) * 2003-04-24 2005-02-28 Pliva-Istra�iva�ki institut d.o.o. Compounds of antiinflammatory effect
US20070196866A1 (en) * 2004-03-13 2007-08-23 Irm Llc Modulators of ion channel trpa1
EP1736465A4 (en) 2004-03-31 2009-06-17 Ajinomoto Kk ANILINE DERIVATIVES
CA2563494A1 (en) * 2004-04-20 2005-11-03 Bayer Healthcare Ag Urea derivatives as antagonists of the vanilloid receptor (vr1)

Also Published As

Publication number Publication date
AU2013202367A1 (en) 2013-05-02
JP2019142914A (ja) 2019-08-29
TW201900217A (zh) 2019-01-01
US8389529B2 (en) 2013-03-05
WO2007073505A2 (en) 2007-06-28
EP1962855A2 (en) 2008-09-03
US20070219222A1 (en) 2007-09-20
AU2013202367B2 (en) 2016-09-15
TW200800264A (en) 2008-01-01
US10351567B2 (en) 2019-07-16
JP2017200953A (ja) 2017-11-09
JP2014065744A (ja) 2014-04-17
US8178542B2 (en) 2012-05-15
TWI649092B (zh) 2019-02-01
AU2016273866B2 (en) 2018-07-05
JP2016020397A (ja) 2016-02-04
TWI423819B (zh) 2014-01-21
AU2006327181A1 (en) 2007-06-28
CN101384261B (zh) 2011-12-07
TWI610684B (zh) 2018-01-11
TW201622749A (zh) 2016-07-01
AU2016273866A1 (en) 2017-01-05
US20110009430A1 (en) 2011-01-13
US20130123283A1 (en) 2013-05-16
CA2634152A1 (en) 2007-06-28
US8541423B2 (en) 2013-09-24
EP1962855B1 (en) 2013-08-21
US20100267750A1 (en) 2010-10-21
WO2007073505A3 (en) 2008-03-13
CN102499921A (zh) 2012-06-20
US20140221401A1 (en) 2014-08-07
US7671061B2 (en) 2010-03-02
US20180093986A1 (en) 2018-04-05
US9815838B2 (en) 2017-11-14
JP6541549B2 (ja) 2019-07-10
JP5858557B2 (ja) 2016-02-10
JP2009521485A (ja) 2009-06-04
TW201412332A (zh) 2014-04-01
CN101384261A (zh) 2009-03-11
ES2436225T3 (es) 2013-12-27

Similar Documents

Publication Publication Date Title
HK1122738A1 (en) Trpa1 inhibitors for treating pain
GB2426008B (en) Treatment process for concrete
AP2870A (en) Odcase inhibitors for the treatment of malaria
ZA200805877B (en) Pyridiazinone derivatives for tumour treatment
EP1959931A4 (en) COMPOSITIONS AND METHODS FOR THE DERMAL TREATMENT OF PAIN
IL198851A0 (en) Methods for treating hypercholesterolemia
IL186963A0 (en) Methods and compositions for treating pain
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
IL183889A0 (en) Treatment method
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
EP1890712A4 (en) COMPOSITIONS AND METHODS FOR TREATING PAIN
EP2083857A4 (en) METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA
IL188430A0 (en) Treatment of tumors
ZA200705278B (en) Method for enhancing acrylamide decomposition
EP1909854A4 (en) METHOD FOR TREATING CANCER
IL178920A0 (en) Treatment for pancreatic cancer
EP1940397A4 (en) METHOD FOR TREATING HYPERTONIA
EP1890690A4 (en) MAO-B INHIBITORS FOR TREATING OBESITY
EP1830847A4 (en) CANCER TREATMENT
HK1139856A1 (en) Methods for treating acute pain
EP1883405A4 (en) METHODS OF TREATING NEPHROLITHIASIS
PL381823A1 (pl) Leczenie czynności napadowej z zastosowaniem inhibitorów ICE
EP1951238A4 (en) PROCESS FOR THE TREATMENT OF CHRONIC PAIN
ZA200904478B (en) Novel therapeutic use for treating leukaemia

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20201220